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Modular synthesis of thirty lead-like scaﬀolds
suitable for CNS drug discovery†
Joan Mayol-Llina`s, a William Farnaby‡b and Adam Nelson *ac
A modular synthetic approach was developed that yielded thirty
diverse lead-like scaﬀolds suitable for CNS drug discovery.
Controlling molecular properties is a challenge that is intrinsic
to drug discovery.1 The challenge is intensified in central nervous
system (CNS) programmes in order that CNS drugs are able to
cross the blood–brain barrier.2 The properties of drugs differ
from those of high-quality lead molecules since molecular
weight, lipophilicity and complexity tend to increase during
optimisation.3 Sourcing large numbers of lead-like screening
compounds4 is, however, a significant challenge that is heigh-
tened by the limited scaffold diversity of historically explored
chemical space.5 To address this challenge, the development of
new synthetic methods to support discovery applications is
being increasingly informed by prospective molecular property,
diversity and novelty analyses.6,7 To facilitate the exploration of
lead-like space for CNS drug discovery,8 we recently adapted a
multi-parameter optimisation (MPO) system8b for scoring CNS
drugs.9 We have now exploited our MPO scoring system to
guide the development and exemplification of a unified syn-
thetic approach to diverse sp3-rich10 lead-like scaffolds suitable
for CNS drug discovery.11 In addition, the approach was
designed to yield scaffolds adhering to accepted CNS design
principles: small and rigid scaffolds8a that could yield screening
compounds lacking functionality that could contribute to poor
permeability and high efflux (e.g. carboxylate and sulfonyl groups
and multiple amides, basic centres and hydrogen bond donors).8e
These characteristics were largely captured in our filtering and
scoring process.
Our synthetic approach (Scheme 1) exploits cyclisation pre-
cursors 1 with an embedded ring system (blue) and up to four
functional group handles (green, light blue, beige and yellow
blobs). It was envisaged that product scaﬀolds would be formed
by reaction between pairs of functional groups, in some cases
in conjunction with an external reactant (red). Crucially, the
approach should result in significant product scaﬀold diversity
including fused (light blue to yellow e.g. 2; light blue to green
e.g. 3), bridged (green to beige e.g. 4) and spirocyclic (green to
yellow e.g. 5 and 6) ring systems.
A range of cyclisation precursors 1 was prepared (Scheme 2).
For example, reaction of the lithium enolate of 7 with the
carbonyl imidazole 8 (- 9),12 and base-catalysed reaction with
the a-NHBoc sulfone 10, gave the b-keto ester 11; Pd-catalysed
Scheme 1 Envisaged approach for the synthesis of diverse lead-like
scaﬀolds.
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decarboxylative allylation13 then gave the exemplar cyclisation
precursor 1a (panel A).
A toolkit of cyclisations was developed using the exemplar
substrate 1a (Scheme 3). Initially, cyclisations to give fused
Scheme 2 Synthesis of the cyclisation precursors 1. Panel A: Synthesis of 1a. Panel B: Other cyclisation precursors prepared (see ESI†).
Scheme 3 Identification of cyclisations for the synthesis of lead-like scaﬀolds using the precursor 1a (bold box). Scaﬀolds prepared using prioritised
(coloured background; see Scheme 4) and other (dashed boxes) methods are shown. The functional groups that react to form rings are denoted by
colour. Methods: A: disiamylborane, THF, 0 1C then NaBO34H2O, THF–H2O; B: Et3SiH, TFA, CH2Cl2 then Boc2O, Et3N, CH2Cl2; C: O3, CH2Cl2, 78 1C
then Me2S, CH2Cl2; D: BnNH2, NaBH(OAc)3, CH2Cl2; E:
iBu2AlH, CH2Cl2, 78 1C; F: I2, NaHCO3, MeCN; G: tBuOK, THF, 0 1C; H: paraformaldehyde, TFA,
MeOH, 65 1C; I: PhCHO, TFA, MeOH, 65 1C; J: NaH, BnBr, cat. Bu4NI, THF, 0 1C; K: 3-bromopyridine, 5 mol% Pd(OAc)2, 10 mol% DPE-Phos, Cs2CO3,
dioxane, 105 1C; L: Ac2O, pyridine; M: MsCl, Et3N, CH2Cl2 then TFA, CH2Cl2 then Et3N, CH2Cl2 then Boc2O, Et3N, CH2Cl2; N: PDC, celite, CH2Cl2;
O: NaBH(OAc)3, AcOH; P: cat. TsOH, MeOH; Q: PhMgBr, CuBrMe2S, Et2OBF3, Et2O, 0 1C.
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scaﬀolds were investigated that involved the ketone (light blue)
and either the alkene (yellow) or the Boc-protected amine
(green) in the cyclisation precursor 1a. Hydroboration–oxidation
of 1a gave the hemiacetal 12 which was reduced (Et3SiH, TFA) to
give, after reprotection, 13 as a single diastereomer. Ozonolysis of
1a gave the hemiaminals 14 which, on treatment with benzyl-
amine and NaBH(OAc)3, underwent double reductive amination
to yield 15 as a 83 : 17 mixture of diastereomers. Alternatively,
reduction of the ketone 1a with iBu2AlH gave the corresponding
secondary alcohol 16a which iodocyclised to give 17 with high
diastereoselectivity. Finally, treatment of the alcohol 16a with
tBuOK gave the fused bicyclic carbamate 18.
Cyclisations between the distal a carbon (beige) and the
Boc-protected amine (green) yielded bridged scaﬀolds. Thus,
intramolecular Mannich reaction14 with either formaldehyde
(- 19) or benzaldehyde (- 4) gave the bridged scaﬀolds.
Finally, cyclisations between the Boc-protected amine
(green) and the alkene (yellow) in 1a gave spirocyclic scaﬀolds.
Iodocyclisation of benzyl-protected 20 gave 21 (dias: 77 : 23),
whilst Pd-catalysed aminoarylation15 with 3-bromopyridine
gave the spirocycle 6. Alternatively, hydroboration–oxidation
of acetyl-protected 22a, followed by sulfonylation and cyclisation,
gave, after reprotection, the spirocycle 24 in 57% overall yield.
Finally, ozonolysis of 22a gave a mixture of hemiaminals 25 that
Scheme 4 Eighteen additional scaﬀolds prepared using the prioritised cyclisation toolkit. Standard methods: A: disiamylborane, THF, 0 1C then
NaBO34H2O, THF–H2O; B: Et3SiH, TFA, CH2Cl2 then Boc2O, Et3N, CH2Cl2; C: O3, CH2Cl2, 78 1C then Me2S, CH2Cl2; E: iBu2AlH, CH2Cl2, 78 1C;
G: tBuOK, THF, 0 1C; L: Ac2O, pyridine; M: MsCl, Et3N, CH2Cl2 then TFA, CH2Cl2 then Et3N, CH2Cl2 then Boc2O, Et3N, CH2Cl2; N: PDC, celite, CH2Cl2;
O: NaBH(OAc)3, AcOH. See ESI† for diastereoselectivities.
a See ESI† for details of method variations.
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could be converted into three different spirocyclic scaffolds:
oxidation with PDC gave the g-lactam 26; reduction with
NaBH(OAc)3 in AcOH gave 27; and conversion into the aminals
28 and treatment with PhMgBr and CuBrMe2S gave 29.
In total, twelve scaﬀolds16 were prepared from the precursor
1a using the toolkit of cyclisation reactions. High scaﬀold
diversity was possible, with product scaﬀolds based on fused,
spiro and bridged bicyclic ring systems.
The toolkit of cyclisations was exploited in the synthesis of
additional scaﬀolds by changing the precursor 1 (Scheme 4).
Product scaﬀolds were selected on the basis of the potential of
their derivatives to serve as high-quality leads for CNS drug
discovery.9 Thus, potential scaﬀolds were decorated once or
twice with exemplar capping groups, and the CNS lead-likeness
of the resulting virtual compounds scored (see ref. 9 and ESI†).
Thus, desirability scores (0.05–1) were determined for six
properties (clog P; clogD at pH 7.4; pKa; number of H bond
donors; molecular weight; and topological polar surface area),
and summed to give a CNS Lead MPO score (0.3–6) (Fig. 1).
Lead-like scaffolds for CNS drug discovery would have many
derivatives with high (4B4) CNS LeadMPO scores. In addition, the
five cyclisations that had proceeded in high yield and diastereos-
electivity with 1a were prioritised (see Scheme 3).
Remarkably, our synthetic approach was highly modular. By
varying both the precursor (1a–g) and the cyclisation, it was
possible to vary independently the rings in product scaffolds.17
The approach was also highly efficient, delivering 30 scaffolds
in a total of 51 steps from the precursors 1a–g.18 We note that,
in addition to specific application in CNS drug discovery,
simple derivatives of scaffolds would be highly distinctive
fragments with suitable properties for fragment-based discovery.19
In conclusion, a highly modular and eﬃcient approach for
the synthesis of structurally diverse molecular scaﬀolds was
developed. Crucially, it was demonstrated that independent
variation of the rings within the scaﬀolds was possible,
enabling the synthesis of thirty diverse and lead-like molecular
scaﬀolds suitable for CNS drug discovery programmes. We thank
Takeda, the University of Leeds and EPSRC (EP/N025652/1) for
funding, and Dr Andrew Ayscough for discussions.
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